8223 (8223) Fair Value & Analysis

Healthcare · Market cap HK$117M

8 8223 8223 · HK

PriceHK$0.2270

Fair ValueHK$0.0600

Upside-73.6%

Quality41/100

Watch 8223 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$0.0500 – HK$0.2100

Fair value as of: Jul 2, 2026

From 6 valuation models · updated today

Share price −29.1% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$0.2270 – HK$1.65 · fair‑value band HK$0.0500 – HK$0.2100 · the HK$0.2270 price screens above the HK$0.0600 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

8223 (8223) currently trades at HK$0.2270, while our model-based Fair Value estimate is HK$0.0600 — implying the stock looks roughly 73.6% overvalued today. We read business quality at 41/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, 8223 generated revenue of HK$482M at a net margin of -2.2%. Revenue declined 13.7% year over year. It earns a return on equity of -3.6%. Net debt stands at HK$228M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$482M

Revenue growth (YoY) -13.7%

Net margin -2.2%

Return on equity -3.6%

Free cash flow −HK$36.3M FY2025

Operating margin -3.2%

More key figures

EPS (TTM) HK$0.0200

EPS growth (YoY) +11.3%

Net debt HK$228M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

8223 reported revenue of HK$503M in FY2025 versus HK$119M in FY2021, a compound +43.3%/yr. Reported net income was −HK$10.4M in FY2025.

Revenue +43.3%/yr

FY21 HK$119M

FY22 HK$325M

FY23 HK$498M

FY24 HK$552M

FY25 HK$503M

Net income

FY21 HK$5.5M

FY22 HK$15.8M

FY23 HK$14.6M

FY24 −HK$53.0M

FY25 −HK$10.4M

Is 8223 fairly valued? → Check now

Similar stocks

6 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
McKesson Corporation M1CK34	R$1,022	R$1,243	+22%
Cencora, Inc C1CO34	R$709.32	R$400.70	-44%
Cardinal Health, Inc CAH	$216.30	$110.75	-49%
Sigma Healthcare Limited SIGGF	$2.35	$0.7800	-67%
SIG SIG	A$2.76	A$0.3300	-88%
Shanghai Pharmaceuticals Holding 601607	¥16.34	¥34.72	+112%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 8223 (8223) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.0600 versus a price of HK$0.2270 — about −74% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 8223?

Our model-based fair value for 8223 is HK$0.0600 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.2270.

What is the quality score of 8223?

8223 has a Quality Score of 41/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 8223 (8223)?

8223 reported trailing-twelve-month revenue of about HK$482M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 8223?

The net profit margin of 8223 is about -2.2%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.